NCT-503  ≥99%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
包装规格:2mg 5mg 25mg 50mg 100mg in glass bottle
产品简介:NCT-503是phosphoglycerate dehydrogenase (PHGDH)抑制剂,IC50为2.5 μM。NCT-503对其他脱氢酶基本没有活性,对所检测的168种GPCRs没有或仅具有微弱的交叉反应性。
溶解性:溶于DMSO(50 mg/mL)
储备液保存:-80°C, 2 years -20°C, 1 year
体内实验:1、请依序添加每种溶剂: 50% PEG300 →50% saline Solubility: 10 mg/mL (24.48 mM); Suspended solution; Need ultrasonic 2、请依序添加每种溶剂: 10% DMSO→ 40% PEG300 →5% Tween-80→ 45% saline Solubility: 2.5 mg/mL (6.12 mM); Suspended solution; Need ultrasonic 此方案可获得 2.5 mg/mL (6.12 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3、请依序添加每种溶剂: 10% DMSO→90% corn oil Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (6.12 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 4、请依序添加每种溶剂: 0.5% methylcellulose→ 0.2% Tween 80 Solubility: 2 mg/mL (4.90 mM); Suspended solution; Need ultrasonic <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
靶点:PHGDH(Cell-free):2.5 μM
体外研究:Human phosphoglycerate dehydrogenase (PHGDH) catalyzes the first, rate-limiting step in the canonical glucose-derived serine synthesis pathway. NCT-503, a PHGDH inhibitor, inhibits serine synthesis from 3-phosphoglycerate in cells (IC50=2.5 µM). NCT-503 is inactive against a panel of other dehydrogenases and shows minimal cross-reactivity in a panel of 168 GPCRs. Competition studies of NCT-503 against 3-phosphoglycerate (3-PG) and the co-substrate NAD+ reveal a non-competitive mode of inhibition with respect to both 3-PG and NAD+. NCT-503 has EC50s of 8–16 µM for the PHGDH-dependent cell lines, a 6- to 10-fold higher EC50 for MDA-MB-231 cells, and no toxicity towards other PHGDH-independent cell lines.
体内研究:NCT-503 exhibits favorable absorption, distribution, metabolism and excretion (ADME) properties. NCT-503 has good exposure, half-life (2.5 hr) and Cmax (20 µM in plasma) following intraperitoneal administration with significant partitioning into the liver and brain. NCT-503 treatment reduces the growth and weight of PHGDH-dependent MDA-MB-468 xenografts but does not affect the growth or weight of PHGDH-independent MDA-MB-231 xenografts.
保存条件:-20°C
注意事项:1、为了您的安全和健康,请穿实验服并戴一次性手套操作。 2、以上信息仅做参考交流之用。